Catalyst

Slingshot members are tracking this event:

Gilead (GILD) Presents Data from Open-Label Proof-of-Concept Study Evaluating GS-0976 in Non-Alcoholic Steatohepatitis (NASH)

Source Link:
http://www.gilead.com/news/press-releases/2017/4/gilead-presents-proofofconcept-data-for-gs0976-in-nonalcoholic-steatohepatitis-nash-at-the-international-liver-congress-2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Apr 21, 2017
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Open-label, Proof-of-concept, Gs-0976, Advanced Non-alcoholic Steatohepatitis, Nash
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.